|1.||Matsumura, Yasuo: 8 articles (07/2012 - 08/2004)|
|2.||Bagnato, Anna: 8 articles (01/2007 - 08/2002)|
|3.||Rosanò, Laura: 7 articles (01/2007 - 08/2002)|
|4.||Spinella, Francesca: 6 articles (04/2006 - 08/2002)|
|5.||Natali, Pier Giorgio: 6 articles (04/2006 - 08/2002)|
|6.||Nicotra, Maria Rita: 6 articles (04/2006 - 08/2002)|
|7.||Di Castro, Valeriana: 6 articles (04/2006 - 08/2002)|
|8.||Opgenorth, T J: 6 articles (12/2001 - 01/2000)|
|9.||Wessale, J L: 5 articles (11/2000 - 01/2000)|
|10.||Ohkita, Mamoru: 4 articles (07/2012 - 04/2007)|
|1.||Prostatic Neoplasms (Prostate Cancer)
04/15/2007 - "In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer."
11/01/2000 - "ABT-627 is a potent endothelin-A (ET(A))-selective antagonist with a Ki value at 0.034 nM for the human ET(A) receptor, and is currently being used in clinical studies for prostate cancer. "
07/01/1999 - "COX-2 receptor modulation has a role in the treatment of bladder cancer, whilst the endothelin receptor antagonist ABT-627 (Abbott International Ltd) may prove effective in the treatment of prostate cancer. "
04/15/2007 - "Therefore, the goal of our study was to obtain preclinical data supporting our hypothesis that the combined use of ET(A) receptor antagonist (ABT-627; Atrasentan) with Taxotere will be superior in inducing apoptosis in vitro and inhibiting tumor growth in vivo in a SCID-hu model of experimental bone metastasis induced by C4-2b prostate cancer cells. "
01/25/2005 - "Postischemic cardiac dysfunction and NE overflow in the heart of ET(B) receptor-deficient homozygous (sl/sl) rats were highly observed compared with cases in wild-type rats, and exaggerated responses to ischemia/reperfusion in sl/sl rats were abolished by ABT-627 treatment. "
05/01/1998 - "A-127722 administered simultaneously with L-NNA completely prevented the increase in proteinuria (39+/-8 mg/d) and glomerular ischemia. "
07/01/2012 - "On the other hand, the beneficial effects of ABT-627 (1 and 3 μM) on NE overflow (carrier-mediated release) and cardiac dysfunction were also observed in 40-minute ischemia, whereas those were not improved by treatment with candesartan (10 and 100 nM and 1 μM). "
07/01/2012 - "Candesartan (10 and 100 nM) and ABT-627 (3 μM) suppressed excessive NE overflow (exocytotic release) in the coronary effluent from the heart exposed to 20-minute ischemia. "
07/01/2012 - "Candesartan (selective AT1R antagonist) and ABT-627 (selective ET(A)R antagonist) were perfused, beginning 15 minutes before ischemia. "
|3.||Vascular System Injuries
11/01/2004 - "Similarly, chronic treatment with ABT-627 totally abolished the systemic and renal vasoconstriction caused by injected ET-1 in rats with congestive heart failure, whereas A192621 potentiated these effects. "
11/01/2004 - "Interestingly, treatment with either ABT-627 or A192621 significantly decreased cardiac hypertrophy in rats with congestive heart failure. "
11/01/2004 - "It has previously been demonstrated that acute administration of ABT-627 (endothelin-A blocker) abolished systemic and renal vasoconstriction in controls and rats with congestive heart failure induced by a surgically created aortocaval fistula (Abassi et al. Clin Sci (Lond) 2002;103:S245-S248). "
11/01/2004 - "Chronic treatment of animals with congestive heart failure with ABT-627 did not influence daily sodium excretion, whereas treatment with A192621 significantly improved daily sodium excretion. "
11/01/2004 - "The present study examined the renal and systemic effects of chronically administered ABT-627 (24 mg/kg per day) or A-192621 (72 mg/kg per day) for 7 days via osmotic minipumps inserted intraperitoneally on the day of operation of sham controls and rats with congestive heart failure. "
|5.||Hypertension (High Blood Pressure)
08/01/2010 - "Prior to administration of ABT-627, AngII-HS and AngII-HS plus ABT-627 groups displayed robust hypertension (mean arterial pressure (MAP), 170 +/- 5 and 165 +/- 5 mm Hg versus 110 +/- 3 mm Hg in normal salt control rats at day 7, P < 0.05). "
07/01/1997 - "Therefore, although the ETA receptor antagonist A-127722 can inhibit ETA-mediated hypertension, it has no effect on hypertension produced by a reduction in renal mass. "
03/01/2003 - "Both drugs were effective in preventing the progression of hypertension in rhEPO-treated rats although ABT-627 was more potent than ridogrel. "
11/28/2000 - "Chronic treatment with ABT-627, an ET(A) receptor antagonist, completely suppressed DOCA-salt-induced hypertension in both groups. "
05/01/1998 - "Rats received A-127722.5 (30 mg/kg/day) or LU 135252 (50 mg/kg/day) in their drinking water since induction of hypertension. "
|4.||Endothelin Receptors (Endothelin Receptor)
|5.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|6.||Matrix Metalloproteinase 2 (Gelatinase A)
|2.||Heterologous Transplantation (Xenotransplantation)